thyroid cancer | GenomeWeb

thyroid cancer

Veracyte said that Quest’s access to half of the physicians and hospitals in the US will provide patients with broader access to the Afirma GEC.

The test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears in order to differentiate benign thyroid nodules from malignant ones.

The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.

The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.

The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.

The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.

Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.

Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.

When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.

Pages

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.